These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23329066)

  • 1. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
    Jones R; Vuky J; Elliott T; Mead G; Arranz JA; Chester J; Chowdhury S; Dudek AZ; Müller-Mattheis V; Grimm MO; Gschwend JE; Wülfing C; Albers P; Li J; Osmukhina A; Skolnik J; Hudes G
    Invest New Drugs; 2013 Aug; 31(4):1001-7. PubMed ID: 23329066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.
    Infante JR; Kurzrock R; Spratlin J; Burris HA; Eckhardt SG; Li J; Wu K; Skolnik JM; Hylander-Gans L; Osmukhina A; Huszar D; Herbst RS
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):165-72. PubMed ID: 21638123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.
    Gerecitano JF; Stephenson JJ; Lewis NL; Osmukhina A; Li J; Wu K; You Z; Huszar D; Skolnik JM; Schwartz GK
    Invest New Drugs; 2013 Apr; 31(2):355-62. PubMed ID: 22615058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.
    Kantarjian HM; Padmanabhan S; Stock W; Tallman MS; Curt GA; Li J; Osmukhina A; Wu K; Huszar D; Borthukar G; Faderl S; Garcia-Manero G; Kadia T; Sankhala K; Odenike O; Altman JK; Minden M
    Invest New Drugs; 2012 Jun; 30(3):1107-15. PubMed ID: 21494838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
    Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
    Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
    Pulido M; Roubaud G; Cazeau AL; Mahammedi H; Vedrine L; Joly F; Mourey L; Pfister C; Goberna A; Lortal B; Bellera C; Pourquier P; Houédé N
    BMC Cancer; 2018 Feb; 18(1):194. PubMed ID: 29454321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors.
    Esaki T; Seto T; Ariyama H; Arita S; Fujimoto C; Tsukasa K; Kometani T; Nosaki K; Hirai F; Yagawa K
    Arch Drug Inf; 2011 Jun; 4(2):23-31. PubMed ID: 21765863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells.
    Marquis L; Tran M; Choi W; Lee IL; Huszar D; Siefker-Radtke A; Dinney C; McConkey DJ
    Cancer Biol Ther; 2012 May; 13(7):477-86. PubMed ID: 22361733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
    Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
    Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.
    Theoclitou ME; Aquila B; Block MH; Brassil PJ; Castriotta L; Code E; Collins MP; Davies AM; Deegan T; Ezhuthachan J; Filla S; Freed E; Hu H; Huszar D; Jayaraman M; Lawson D; Lewis PM; Nadella MV; Oza V; Padmanilayam M; Pontz T; Ronco L; Russell D; Whitston D; Zheng X
    J Med Chem; 2011 Oct; 54(19):6734-50. PubMed ID: 21899292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Tang PA; Siu LL; Chen EX; Hotte SJ; Chia S; Schwarz JK; Pond GR; Johnson C; Colevas AD; Synold TW; Vasist LS; Winquist E
    Invest New Drugs; 2008 Jun; 26(3):257-64. PubMed ID: 18038218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
    Ko YJ; Canil CM; Mukherjee SD; Winquist E; Elser C; Eisen A; Reaume MN; Zhang L; Sridhar SS
    Lancet Oncol; 2013 Jul; 14(8):769-76. PubMed ID: 23706985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
    Lee CW; Bélanger K; Rao SC; Petrella TM; Tozer RG; Wood L; Savage KJ; Eisenhauer EA; Synold TW; Wainman N; Seymour L
    Invest New Drugs; 2008 Jun; 26(3):249-55. PubMed ID: 17962907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
    Knox JJ; Gill S; Synold TW; Biagi JJ; Major P; Feld R; Cripps C; Wainman N; Eisenhauer E; Seymour L
    Invest New Drugs; 2008 Jun; 26(3):265-72. PubMed ID: 18196204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
    Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH
    Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.
    Wakui H; Yamamoto N; Kitazono S; Mizugaki H; Nakamichi S; Fujiwara Y; Nokihara H; Yamada Y; Suzuki K; Kanda H; Akinaga S; Tamura T
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):15-23. PubMed ID: 24752449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
    Holen KD; Belani CP; Wilding G; Ramalingam S; Volkman JL; Ramanathan RK; Vasist LS; Bowen CJ; Hodge JP; Dar MM; Ho PT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):447-54. PubMed ID: 20461380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
    Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
    LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA
    Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.